- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05278520
Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis (OASEQ)
Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific objectives of this project are:
- Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B, D) determine what are the key molecular pathways activated in OA.
- To determine if some of the blood-derived immune cell populations could be used as biomarkers for OA.
- To map the whole transcriptome of OA and non-arthritic control tissue while keeping the morphological context with spatial transcriptomics technologies.
- Further differentiation and identification of OA endotypes utilizing the single-cell and spatial data.
The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Lea Mikkola, PhD
- Phone Number: +358404143300
- Email: limikk@utu.fi
Study Locations
-
-
Uusimaa
-
Espoo, Uusimaa, Finland
- Recruiting
- Helsinki University Hospital
-
Contact:
- Anna Vasara, MD, PhD
- Email: anna.vasara@hus.fi
-
Principal Investigator:
- Anna Vasara, MD, PhD
-
-
Varsinais-Suomi
-
Turku, Varsinais-Suomi, Finland
- Active, not recruiting
- PET-centre, University of Turku
-
Turku, Varsinais-Suomi, Finland
- Active, not recruiting
- Turku Bioscience, University of Turku
-
Turku, Varsinais-Suomi, Finland
- Recruiting
- Turku University Hospital
-
Contact:
- Pjotr Sarantsin, MD
- Email: Pjotr.Sarantsin@tyks.fi
-
Principal Investigator:
- Pjotr Sarantsin, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria for the main (OA) study:
Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty.
Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.
----
Inclusion Criteria for the Rheumatoid sub-study:
Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.
----
Exclusion Criteria:
- The body mass index must be below 35
- Age < 18 or > 74
- The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.
For the Rheumatoid sub-study, the exclusion criteria are the same as above except for the RA.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
OA cases
Twenty-five adult patients who have hip osteoarthritis.
|
Hip joint replacement surgery.
Elective for RA and OA cases.
|
RA cases
Twenty-five adult patients who have rheumatoid arthritis in the hip joint.
|
Hip joint replacement surgery.
Elective for RA and OA cases.
|
Non-arthritic controls
Fifteen adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
|
Hip joint replacement surgery.
Elective for RA and OA cases.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of cell populations in OA
Time Frame: Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
Characterization of cell populations found in different synovial tissues and blood derived samples of OA patients utilising scRNAseq solutions.
|
Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
Comparison of cell populations between OA cases and controls
Time Frame: Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
The investigators will determine how the cell composition differs between arthritic and corresponding non-arthritic tissues utilising scRNAseq solutions.
|
Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
Cellular landscape in OA
Time Frame: Starting during the second quarter of 2023, ending by the last quarter of 2024.
|
The investigators will map the transcriptional and regulatory landscape of OA at single-cell and tissue (spatial) level.
|
Starting during the second quarter of 2023, ending by the last quarter of 2024.
|
Key molecular pathways of OA
Time Frame: Starting during the second quarter of 2023, ending by the last quarter of 2024.
|
The investigators will determine what are the key molecular pathways activated in OA.
|
Starting during the second quarter of 2023, ending by the last quarter of 2024.
|
Comparison of disease mechanisms between RA and OA
Time Frame: Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
In the Rheumatoid sub-study the investigators will explore the differences in the disease mechanisms between OA and RA by comparing synovial tissues and peripheral blood sample constituents.
|
Starting during the last quarter of 2022, ending by the last quarter of 2024.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers for OA
Time Frame: Starting during the second half of 2023, ending by the first half of 2025.
|
The investigators will investigate if some of the blood-derived immune cell populations could be used as biomarkers for OA.
|
Starting during the second half of 2023, ending by the first half of 2025.
|
OA endotypes
Time Frame: Starting during the first half of 2024, ending by the second half of 2025.
|
The investigators aim to identify and further differentiate OA endotypes by utilizing the single-cell and spatial data.
|
Starting during the first half of 2024, ending by the second half of 2025.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lea Mikkola, PhD, Turku Bioscience, University of Turku
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022OASEQ
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
David Grant U.S. Air Force Medical CenterCompleted
-
TcLand Expression S.A.European CommissionTerminatedRheumatoId ArthritisFrance, Netherlands, Turkey, Czechia, Israel
Clinical Trials on Total hip arthroplasty
-
Smith & Nephew, Inc.RecruitingAdvanced Degeneration of the Hip Joint | Revision of the Hip JointUnited States, Canada, Australia, Hong Kong, India
-
Suzhou MicroPort OrthoRecon Co. LTDCompleted
-
DePuy OrthopaedicsTerminatedOsteoarthritis | Degenerative Arthritis | Revision ArthroplastyCanada
-
Rothman Institute OrthopaedicsCompleted
-
Istituto Clinico HumanitasCompleted
-
Orthopedic Hospital Vienna SpeisingCompletedTotal Hip ArthroplastyAustria
-
Norwegian University of Science and TechnologyOrtoMedic A/S, Oslo; Scandinavian Customized Prosthesis (SCP)CompletedOsteoarthritis, Hip
-
NHS LothianTerminatedHip FracturesUnited Kingdom
-
Western University, CanadaNot yet recruiting
-
Zimmer BiometTerminatedJoint Diseases | Osteoarthritis, Hip | Avascular Necrosis of Hip | Congenital Dysplasia of the Hip | Degenerative Joint Disease of Hip | Rheumatoid Arthritis of Hip | Post-Traumatic Osteoarthritis of HipCanada